ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors

British Journal of Pharmacology

Volumn 129, Issue 2, 2000, Pages 275-282

  Jarvis, G E ^a   Humphries, R G ^a   Robertson, M J ^a   Leff, P ^a  

^a R D Charnwood   (United Kingdom)

Author keywords

Adenosine 3' phosphate 5' phosphate; ADP; Anti thrombotic agents; AR C67085; Heparinized platelet rich plasma; P(2T) receptors; Platelet aggregation

Indexed keywords

2 PROPYLTHIO BETA GAMMA DICHLOROMETHYLENE ADENOSINE TRIPHOSPHATE; ADENOSINE DIPHOSPHATE; BETA,GAMMA DICHLOROMETHYLENE 2 PROPYLTHIOADENOSINE TRIPHOSPHATE; PURINE P2 RECEPTOR; PURINE P2T RECEPTOR; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADULT; ALGORITHMS; BINDING, COMPETITIVE; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THROMBOXANE A2;

EID: 0033955027     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703046     Document Type: Article

References (39)

1. Bates, D.M. & Watts, D.G. (1988). Nonlinear Regression Analysis and its Applications. Chapter 3. Practical considerations in nonlinear regression. New York: John Wiley & Sons Inc., pp. 67-133.
2. Boneu, B. & Destelle, G. (1996). Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb. Haemost., 76, 939-943.
3. Born, G.V.R. (1962). Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 194, 927-929.
4. Born, G.V.R. & Cross, M.J. (1963). The aggregation of blood platelets. J. Physiol., 168, 178-195.
5. 1 receptor. Mol. Pharmacol., 50, 1323-1329.
6. Burnstock, G. (1978). A basis for distinguishing two types of purinergic receptor. In Straub, R.W. & Bolis, L. eds. Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. New York: Raven Press, pp.107-118.
7. Cusack, N.J. & Hourani, S.M.O. (1982). Adenosine 5'-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br. J. Pharmacol., 76, 221-227.
8. Daniel, J.L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J.B & Kunapuli, S.P. (1998). Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem., 273, 2024-2029.
9. De Lean, A., Hancock, A.A. & Lefkowitz, R.J. (1982). Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol., 21, 5-16.
10. De Lean, A., Munson, P.J. & Rodbard, D. (1978). Simultaneous analysis of families of sigmoidal curves: application to bioassay, radiologand assay, and physiological dose-response curves. Amer. J. Physiol., 235, E97-E102.
11. (ADP)-receptors. Br. J. Pharmacol., 124, 157-164.
12. Fredholm, B.B., Abbracchio, M.P., Burnstock, G., Daly, J.W., Harden, T.K., Jacobsen, K.A., Leff, P. & Williams, M. (1994). Nomenclature and classification of purinoceptors. Pharmacol. Rev., 46, 143-156.
13. Fredholm, B.B., Abbracchio, M.P., Burnstock, G.B., Dubyak, G.R., Harden, T.K., Jacobsen, K.A., Schwabe, U. & Williams, M. (1997). Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol. Sci., 18, 79-81.
14. Gaarder, A., Jonsen, J., Laland, S., Hellem, A. & Owren, P.A. (1961). Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature, 192, 531-532.
15. Gachet, C., Cattaneo, M., Ohlmann, P., Hechler, B., Lecchi, A., Chevalier, J., Cassel, D., Mannucci, P.M. & Cazenave, J-P. (1995). Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br. J. Haematol., 91, 434-444.
16. Gachet, C., Hechler, B., Léon, C., Vial, C., Leray, C., Ohlmann, P. & Cazenave, J-P. (1997). Activation of ADP receptors and platelet function. Thromb. Haemost., 78, 271-275.
17. Geiger, J. Hönig-Liedl, P., Schanzenbächer, P. & Walter, U. (1998). Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur. J. Pharmacol., 351, 235-247.
18. Gordon, J.L. (1986). Extracellular ATP: effects, sources and fate. Biochem. J., 233, 309-319.
19. Hancock, A.A., Bush, E.N., Stanisic, D., Kyncl, J.J. & Lin, C.T. (1988). Data normalization before statistical analysis: keeping the horse before the cart. Trends Pharmacol. Sci., 9, 29-32.
20. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br. J. Haematol., 103, 858-866.
21. 1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood, 92, 152-159.
22. Hourani, S.M.O., Hall, D.A. & Nieman, C.J. (1992), Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate. Br. J. Pharmacol., 105, 453-457.
23. Humphries, R.G., Tomlinson, W., Clegg, J.A., Ingall, A.H., Kindon, N.D. & Leff, P. (1995). Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br. J. Pharmacol., 115, 1110-1116.
24. 2T receptors. Br. J. Pharmacol., 124 (Proc. Suppl.), 32P.
25. Jin, J., Daniel, J.L. & Kunapuli, S.P. (1998). Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem., 273, 2030-2034.
26. Jin, J. & Kunapuli, S.P. (1998). Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. U.S.A., 95, 8070-8074.
27. Léon, C., Hechler, B., Vial, C., Leray, C., Cazenave, J-P. & Gachet, C. (1997). The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett., 403, 26-30.
28. Lew, M.J. & Angus, J.A. (1995). Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol. Sci., 16, 328-337.
29. MacFarlane, D.E. & Mills, D.C.B. (1975). The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood, 46, 309-320.
30. 2T purinoceptors in human platelets. J. Biol. Chem., 271, 2879-2881.
31. MacMillan, D.C. (1966). Secondary clumping effect in human citrated platelet-rich plasma produced by adenosine diphosphate and adrenaline. Nature, 211, 140-144.
32. O'Brien, J.R. (1968). Effects of salicylates on human platelets. Lancet, i, 779-783.
33. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb. Haemost., 62, 968-976.
34. Savi, P., Beauverger, P., Labouret, C., Delfaud, M., Salel, V., Kaghad, M. & Herbert, J.M. (1998). Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett., 422, 291-295.
35. Savi, P., Bornia, J., Salel, V., Delfaud, M. & Herbert, J.M. (1997). Characterization of P2x1 purinoceptors on rat platelets: effect of clopidogrel. Br. J. Haematol., 98, 880-886.
36. Savi, P., Pflieger, A.M. & Herbert, J.M. (1996). cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coag. Fibrinol., 7, 249-252.
37. Scase, T.J., Heath, M.F., Allen, J.M., Sage, S.O. & Evans, R.J. (1998). Identification of a P2X1 purinoceptor expressed on human platelets. Biochim. Biophys. Res. Commun., 242, 525-528.
38. Vial, C., Hechler, B., Léon, C., Cazenave, J-P. & Gachet, C. (1997). Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb. Haemost., 78, 1500-1504.
39. 2Y purinoceptors and nucleotide receptors) coexisting on endothelial cells. Mol. Pharmacol., 45, 731-736.